Pricing Log in Create free account
Friday 6 November 2026 Export RGEN’s income statement to Excel — free account

Repligen Corporation

RGEN Healthcare Medical Instruments & Supplies

Repligen Corporation’s revenue for fiscal 2025 (year ended December 2025) was $738.3 million, up 16.4% from fiscal 2024.

Revenue
+10.9%
EPS
−351.9%
Free cash flow
−11.5%
Total debt
+3.28%

Quarter to September 2026, against a year earlier

171.17 2.69 +1.60%
Market cap
$10.8B
P/E
0.0×
Fwd P/E
−615×
Dividend yield
—
F-score
6/9
Altman Z
7.49
Beneish M
−2.52
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Repligen Corporation 10-Q filed Oct 30, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed · accepted 4:01 PM ET · Document on sec.gov · Filing index

Red flags

  • Material weakness

    Repligen Corporation’s 10-Q reports a material weakness in internal control over financial reporting

    Except for the material weaknesses described above, there have been no changes in our internal control over financial reporting

    10-Q filed · The filing · sec.gov

  • Share dilution

    Shares outstanding rose 13.6% in a year, to 63.9 million

    10-Q filed · The filing · sec.gov

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Part II, Item 1A, Risk Factors, against the 10-Q filed Jul 29, 2026: 2 removed · 3 modified; 1 with only figures updated